GLP1R and cardiovascular disorder: Additional evidence for the indication was provided in the 2021 ESC Guidelines for the Prevention of Cardiovascular Disease, which recommended GLP-1 RA for individuals with type 2 diabetes and atherosclerotic cardiovascular disease to lower the risk of cardiovascular disease and renal consequences.